Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected Range

  • Bristol Myers Squibb & Co BMY said that its Q4 sales of $11.41 billion fell 5% Y/Y as generic competition impacted sales of its blockbuster cancer drug Revlimid in the U.S. and foreign exchange impacts, partially offset by in-line products (primarily Opdivo) and new product portfolio (primarily Opdualag and Abecma). Analysts estimated Q4 sales of $11.20 billion.
  • Sales of Revlimid fell 32% to $2.3 billion in the quarter.
  • Sales of its cancer immunotherapy Opdivo rose 11% to $2.2 billion. 
  • The company's adjusted EPS of $1.82 declined 1% Y/Y beating the consensus of $1.72.
  • Related: UK Study Finds Pfizer/Bristol Myers Clotting Drug Does Not Help COVID-19 Patients.
  • "With a younger and more diversified portfolio, promising mid-to-late stage registrational assets, and a deep early-stage pipeline, I am confident that the company is well positioned for multiple waves of innovation that will support long-term growth," said Giovanni Caforio, board chair & CEO.
  • Guidance: Bristol Myers Squibb forecasts 2023 adjusted EPS of $7.95 - $8.25 versus the consensus of $8.
  • The company expects revenue to increase by approximately 2% at reported rates and approximately 2%, excluding foreign exchange.
  • Revenues from Revlimid are expected to be approximately $6.5 billion, down from $9.9 billion in 2022.
  • Price Action: BMY shares are up 1.15% at $72.05 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CarePre-Market OutlookMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!